Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$5.18 USD
+0.25 (5.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $5.17 -0.01 (-0.19%) 7:06 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Inozyme Pharma, Inc. [INZY]
Reports for Purchase
Showing records 1 - 20 ( 79 total )
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From the 2024 Wedbush Healthcare Conference
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Pivotal ENPP1 Deficiency Trial Expected to Complete Enrollment in 3Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
FDA Grants Fast Track Designation for INZ-701 in ABCC6 Deficiency
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Topline Data From Pivotal ENERGY-3 Trial Projected for Mid-2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Topline Data From Phase 1/2 Trials of INZ-701 in ABCC6 Deficiency and ENPP1 Deficiency
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Topline Results For INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency Expected Early April
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
INZY Full of ENERGY, and with Adult Topline Data Around the Corner
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Topline Data From Phase 1/2 Trials in Adults With ENPP1 Deficiency and ABCC6 Deficiency Expected 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E